Holen Sie sich die Stockscreener-App
0.6818
4.88%
0.0317
Vorhandelsmarkt:
.68
-0.0018
-0.26%
Schlusskurs vom Vortag:
$0.6501
Offen:
$0.665
24-Stunden-Volumen:
130.19K
Relative Volume:
1.47
Marktkapitalisierung:
$28.65M
Einnahmen:
Nettoeinkommen (Verlust:
$-31.37M
KGV:
-0.4741
EPS:
-1.438
Netto-Cashflow:
$-4.23M
1W Leistung:
+3.60%
1M Leistung:
-24.75%
6M Leistung:
-39.66%
1J Leistung:
-51.99%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.6227
$0.6927
52-Wochen-Spanne:
$0.60
$1.795
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Firmenname
Mira Pharmaceuticals Inc
Sektor
Telefon
813-369-5150
Adresse
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.6818 | 28.65M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,270.75 | 1.13T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.78 | 621.22B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
284.80 | 503.28B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.88 | 369.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.93 | 292.58B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
Roadzen, Inc. (RDZN) stock price, news, quote and history - Yahoo Finance UK
MIRA Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | K6S | US60458C1045 - www.marketscreener.com
MIRA Pharmaceuticals (MIRA) Slips 5.81% to $0.66 as Shares Test Key SupportRelative Volume - https://www.siam.in/
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight - The Manila Times
Earnings Calendar for: - Yahoo Finance
Is Hasbro Stock Underperforming the S&P 500? - barchart.com
What's Behind MIRA Pharmaceuticals, Inc.'s (MIRA) Big Moment in Cannabis Stocks? - Kalkine Media
This Under-the-Radar AI Data Center Stock Just Assigned Its Michigan Campus a Value of Up to $1.25 Billion - Barchart.com
Trump Just Sent Greenland Mines Stock Soaring 370%. How to Play It Here. - Barchart.com
McDonald’s (MCD) Stock Looks Like a Lost Cause — Until You Look at the Data - Barchart.com
Ralph Lauren Stock: Is RL Outperforming the Consumer Cyclical Sector? - Barchart.com
How Is Host Hotels & Resorts’ Stock Performance Compared to Other REIT Stocks? - Barchart.com
CoreWeave Priced an Upsized $3.7 Billion Convertible Note as Capex Spending Spikes. What That Means for CRWV Stock Fans. - Barchart.com
Stocks Retreat as Bond Yields Climb on Fed Rate Hike Fears - Barchart.com
How Is Carnival Corporation Stock Performance Compared to Other Leisure and Entertainment Stocks - Barchart.com
Is Marvell Stock Outperforming the S&P 500? - Barchart.com
Nebius Stock Spikes 4% on Higher Computer Prices. How to Play NBIS Stock Here. - Barchart.com
Why Is Natera (NTRA) Stock Soaring Today - Barchart.com
Stocks Supported as Crude Oil Prices Ease - Barchart.com
APLD’s 250MW Question: The Deal That Could Unlock Applied Digital Stock’s Next Leg Up - Barchart.com
Red Cat CEO Just Sold $1.6 Million of Stock. Wall Street Sees 144% Rally Ahead. - Barchart.com
How Is United Airlines' Stock Performance Compared to Other Global Jets Stocks? - Barchart.com
Is J.B. Hunt Transport Services Stock Outperforming the S&P 500? - Barchart.com
Nebius’s Price Hike Suggests Michael Burry Made a Mistake and Is Shorting the Best Neocloud Stock - Barchart.com
IBM Once Held Nvidia's Spot as Tech's Biggest Name. The Stock Just Crashed 25%. Here's the Comeback Case. - Barchart.com
Stocks Finish Mostly Higher as Crude Prices Fall - Barchart.com
Fluence Energy (FLNC) Stock Trades Down, Here Is Why - Barchart.com
I Sold Micron Before Q2 Earnings and It Fell 23%. Here’s Why I'm Buying Before the Next Report. - Barchart.com
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com Nigeria
MIRA Pharmaceuticals submits Ketamir-2 protocol for IRB review By Investing.com - Investing.com UK
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review - Yahoo Finance
A drug candidate is moving toward its first patient test for nerve pain caused by chemotherapy. MIRA targets Q1 2027. - stocktitan.net
Maxim Group Initiates MIRA Pharmaceuticals(MIRA.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
63% of MIRA Pharmaceuticals (MIRA) shares vote to reelect board and back 2026 auditor - stocktitan.net
Seagate Stock Has Already Exploded. Here’s What Could Send It 99% Higher to $1,600. - Barchart.com
Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com
This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com
Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News
Is Lam Research Stock Outperforming the Nasdaq? - Barchart.com
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com South Africa
MIRA-55 toxicology results advance non-opioid pain program - TipRanks
MIRA Pharmaceuticals reports toxicology data for pain drug candidate - Investing.com
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com UK
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com India
Why Nvidia Stock Looks Attractive... for Some Investors - Barchart.com
Better Than Nvidia: 3 AI Dividend Stocks Leaving It in the Dust - barchart.com
Case Closed: How to Play Super Micro Computer Stock as Smuggling Investigation Ends - Barchart.com
MIRA (MIRA) Update: Holds Near $0.73 on the Day; Key Range: $0.69 and $0.77 Define the Nearby Reference Levels for the Current SessionInitial Balance - vinanet.vn
Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.56%
1.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):